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AV Junction Ablation in
Heart Failure Patients
With Atrial Fibrillation
Treated With Cardiac
Resynchronization Therapy
The Picture Is Now Clear!*
Maurizio Gasparini, MD, Paola Galimberti, MD
Rozzano/Milano, Italy
Cardiac resynchronization therapy (CRT) improves left
ventricular (LV) function and reduces morbidity and mor-
tality (1). Randomized controlled trials enroll virtually only
sinus rhythm (SR) patients, establishing CRT as a class IA
indication for patients in New York Heart Association
(NYHA) functional class II through IV despite optimal
medical therapy, with ejection fraction (EF) 35%, wide
QRS, and SR (2). However, approximately 25% of patients
eligible for CRT experience concomitant atrial fibrillation
(AF). After several observational studies and 2 meta-
analyses, the most recent guidelines qualify patients with
AF as class IIA (1). Therefore, while there is now general
agreement on the indication for CRT in AF patients, their
optimal management may remain a matter of discussion.
See page 719
In this context, the meta-analysis by Ganesan et al. (3) in
this issue of the Journal provides an important contribution
confirming unequivocal favorable results of AV junction
(AVJ) ablation in AF patients treated with CRT.
The problem of optimal “CRT dose” in AF. AF poses a
number of challenges for adequate CRT delivery. An
intrinsic irregular spontaneous AF rhythm may significantly
reduce the percentage of effective biventricular pacing
(BVP%). Even during low-rate AF, phases of completely
effective biventricular capture alternate with phases of com-
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disclose.peting AF rhythm, thereby creating spontaneous, fusion, or
pseudo-fusion beats. Consequently, in patients with AF, the
global effective “CRT dose” may be markedly reduced
compared with SR patients, usually paced in atrial synchro-
nous modality, with short and optimized AV intervals. In
AF patients, lowering heart rate allows better diastolic
filling and increases stroke volume according to the Frank-
Starling mechanism. The regularization of heart rate further
reinforces favorable effects on diastolic function.
Which tools maximize BVP% in AF patients? The spec-
trum of negative chronotropic drugs considered effective in
heart failure (HF) patients with AF is limited and includes
beta-blockers, digoxin, and amiodarone, although the latter
2 may increase morbidity and mortality (4). Some device-
derived features (e.g., conducted AF response, biventricular
trigger, and ventricular rate regulation) are specifically
designed to improve rate control in atrial arrhythmias, and
they should always be initiated. However, if partially effec-
tive at rest (despite higher average rates, which are clearly
deleterious on diastolic function), their efficacy during
exercise seems to be marginal. AVJ ablation is the only tool
that allows complete rhythm regularization and heart rate
control, thus favoring a “pure,” constant delivery of CRT.
Positive effects of AVJ ablation in CRT. SOFT ENDPOINTS.
Soft endpoint improvements have been extensively docu-
mented after CRT, both short-term and long-term in AF
patients. It is important to stress that these benefits seem
more relevant in AF patients treated with AVJ ablation or
spontaneous low-rate AF. The largest experience on this
topic was presented by our group (2) in 2006: this prospec-
tive study specifically assessed the effects of AVJ ablation in
AF patients treated with CRT. Using a predefined protocol,
we showed that significant improvements in NYHA func-
tional class, left ventricular ejection fraction (LVEF), LV
end-systolic volume, and exercise capacity were confined to
those patients treated with AVJ ablation.
In the meta-analysis by Ganesan et al. (3), NYHA func-
ional class improvement was more evident in AVJ ablation
atients, whereas no definitive conclusions were drawn on the
-min walk test, probably due to insufficient data. In this
eta-analysis, only 3 studies reported LVEF modification
fter AVJ ablation: the increase of EF in the AVJ ablation
roup was not statistically superior compared with the group
ithout AVJ ablation, even if the degree of EF improvement
n ablated patients seems to be remarkable (10.3% vs. 4.2%).
A hypothetical explanation for the lack of significance may
e correlated to the limited follow-up. In 2 of the 3 studies
valuating EF (6 and 9 months for Molhoek et al. [5] and
ong et al. [6], respectively, 25 months in our experience [7]),
his is even more important if we consider that, in the majority
f cases, AVJ ablation is performed 2 to 3 months after CRT.
t is reasonable to expect that longer follow-up might have
ermitted the detection of a progressive EF increase after
RT, particularly evident after AVJ ablation.
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eta-analysis of Ganesan et al. (3) focuses on the dramatic
eduction of total and cardiovascular mortality conferred by
VJ ablation. It is surprising to note that in many different
tudies, the mortality rate in nonablated AF patients was
lways approximately 14% per year, whereas in AVJ-ablated
atients, a 3-fold reduction of mortality was observed (8). In
his context, the work by Ganesan et al. (3) would seem to
rovide a definitive conclusion on the survival benefit
onferred by AV node ablation, showing a significant
eduction of both total (risk ratio: 0.42) and cardiovascular
risk ratio: 0.44) mortality.
A questionable point of this paper, however, regards the lack
f correlation between mortality and EF. Because there was no
ignificant difference observed in CRT defibrillator or pacing
evice utilization between patients with or without AVJ
blation, cardiac mortality reduction seems to be driven mainly
y a significant reduction of HF death, which in turn usually
orrelates strictly to EF increase and reverse remodeling.
In the discussion, Ganesan et al. (3) seem to be surprised
y the lack of significant LVEF improvement in the AVJ
blation group with respect to the nonablation group,
espite the dramatic mortality reduction. A possible expla-
ation, in our opinion, may be that a hazard ratio of 0.42 for
otal mortality implies a much better survival in ablated
atients: this determines that the echocardiographic data at
ollow-up of nonablated patients are related only to the 40%
survivors” of this group, clearly with a much better LV
unction and prognosis. The very short follow-up after AVJ
blation in the Molhoek and Dong experiences and the
natural selection bias” associated with the limited number
f “nonablated survivors” might well explain the nonsignif-
cant superior increase of EF in ablated patients.
ADJUNCTIVE POTENTIAL FAVORABLE EFFECTS OF AVJ
ABLATION IN AF AND CRT. AVJ ablation is the most pow-
erful predictor of SR resumption in permanent AF patients
treated with CRT (9). The conversion from AF to SR even
after many years seems to be related to the higher BVP
observed in ablated patients and consequent reverse remod-
eling. Last, but not least, we should always remember the
possibility of inappropriate shocks during fast AF and their
negative impact on quality of life; this problem is completely
abolished by AVJ ablation.
POTENTIAL NEGATIVE ASPECTS OF AVJ ABLATION IN CRT.
AVJ ablation is usually an easy and safe procedure; none-
theless, it is often perceived as a potentially harmful therapy
that should be avoided as much as possible because it causes
pacemaker dependency. However, as correctly reported by
Ganesan et al. (3), no studies on conventional ablate and
pace therapy have reported significant complications during
the follow-up. Furthermore, the aforementioned benefits of
AVJ ablation in this HF population seem to well outweigh
possible risks associated with pacemaker dependency.The presence of 2 ventricular leads should theoretically
protect from problems related to increased lead threshold or
dislocation; in any case, it could be appropriate to perform
AVJ ablation after lead stabilization (at least 2 months).
The long “Gold Rush” to reach 100% BVP. The need to
optimize medical treatment is well established, using the
maximized dosage of beta-blockers and angiotensin-
converting enzyme inhibitors in patients with HF. The
same holds true for optimizing CRT: maximal BVP%
should always be pursued and reached. Currently, there is a
growing body of evidence on the necessity of reaching the
highest possible BVP%. Starting from our arbitrary cutoff of
“theoretically effective” BVP pacing 85%, presented in
2006 (7), during the last 5 years, a substantial amount of
consistent and homogeneous data continuously raised this
“gold rush” standard to 92% and recently to 97.8% (using
home monitoring data on 40,000 patients) (10). This cutoff
seems to highlight the dramatic survival difference in any
patient undergoing CRT, but it seems mandatory in the
subgroup of AF patients. As a matter of fact, the meta-
analysis by Ganesan et al. (3) confirms that the highest
BVP%s and a complete effect of CRT may be achieved in
AF patients only via AVJ ablation.
We may therefore conclude that, currently, AVJ ablation
should always be considered a fundamental step of a
“combined strategy” to obtain the best results of CRT in
this complex HF population.
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